This test detects somatic and germline SNVs, InDels and CNVs mutations in the BRCA1 and BRCA2 genes, covering the entire coding regions of the BRCA1/2 gene and both flanking intron regions, providing information to guide PARP inhibitor therapy in breast and ovarian cancer.